bioRxiv Science⌕ Search

Biology subjects

Missmer, S. A.

Publications and source records attributed to Missmer, S. A..

3 recordsLinked to original sources

Predicting Endometriosis Status and Menstrual Cycle Phase Using DNA Methylation

Endometriosis is a chronic inflammatory disease associated with pelvic pain, infertility, and delayed diagnosis. Growing evidence suggests that altered DNA methylation contributes to disease development and could serve as a biomarker for disease. We developed a leakage-safe machine learning pipeline to classify endometriosis case-control status and menstrual cycle phase using genome-wide DNA methylation data from eutopic endometrial tissue. The dataset consisted of 984 samples profiled using the Illumina Infinium MethylationEPIC array, with measurements across approximately 759,000 CpG sites. Technical variation was corrected using SmartSVA batch correction. Ridge logistic regression models were trained using stratified 80/20 train-test splits, with regularization strength selected via stratified cross-validation. Feature selection approaches included ridge coefficient ranking, per-CpG t-tests, and univariate logistic regression with FDR correction. Model validity was evaluated using label-shuffling analyses. Menstrual cycle phase classification showed strong performance (mean cross-validation AUROC: 0.971, held-out test AUROC: 0.989), reflecting genome-wide hormonally driven methylation. Ridge regression produced lower but meaningful performance for endometriosis classification (mean cross-validation AUROC: 0.854, held-out test AUROC: 0.875). Ridge coefficient-based feature selection identified compact predictive CpG sets, supporting the hypothesis that endometriosis-associated methylation signal is distributed across many loci rather than a few highly predictive CpGs. Pathway enrichment analyses identified substantial enrichment for menstrual cycle phase but limited enrichment for disease status following FDR correction, consistent with a diffuse endometriosis-associated signal. These findings demonstrate that ridge regression can detect methylation patterns associated with both endometriosis and menstrual cycle phase, highlighting the importance of accounting for cycle-related epigenetic variation in endometrial DNA methylation studies.

bioinformatics↗

Targeting NGF but not VEGF or BDNF signaling reduces endometriosis-associated pain in mice

IntroductionEndometriosis is a chronic inflammatory disease that affects [~]10% of women. A significant fraction of patients experience limited or no efficacy with current therapies. Tissue adjacent to endometriosis lesions often exhibits increased neurite and vascular density, suggesting that disease pathology involves neurotrophic activity and angiogenesis. ObjectivesWe aim to evaluate the potential for key tyrosine-kinase-receptor-coupled neurotrophic molecules to contribute to endometriosis-associated pain in mice. MethodsThe levels of VEGFR1 regulators (VEGFA, VEGFB, PLGF, and sVEGFR1) were quantified by ELISA in peritoneal fluid from endometriosis patients undergoing surgery and used to calculate VEGFR1 occupancy. We used genetic depletion, neutralizing antibody, and pharmacological approaches to specifically block ligand (NGF or BDNF) or neurotrophic receptor (VEGFR1, TRKs) in a murine model of endometriosis-associated pain. Endometriosis-associated pain was determined using the von Frey filaments method, quantification of spontaneous abdominal pain-related behavior, and thermal discomfort. Diseases parameters were evaluated by lesion size and prevalence. ResultsWe found that entrectinib (pan-Trk inhibitor) or anti-NGF treatments reduced evoked pain, spontaneous pain, and thermal discomfort. In contrast, even though receptor occupancy revealing that VEGFR1 agonist levels are sufficient to support pain, blocking VEGFR1 signaling via antibody or tamoxifen-induced knockout did not reduce pain or lesion size in mice. Targeting BDNF-TrkB with an anti-BDNF antibody also proved ineffective. ConclusionsThis suggests NGF-TrkA signaling, but not BDNF-TrkB or VEGF-VEGFR1, mediates endometriosis-associated pain. Moreover, entrectinib blocks endometriosis-associated pain and reduces lesion sizes. Our results also indicated that entrectinib-like molecules are promising candidates for endometriosis treatment. Credit author statementConceptualization: T.H. Zaninelli, V. Fattori, and M.S. Rogers; investigation and data curation: T.H. Zaninelli, V. Fattori, O.K. Heintz, K.R. Wright; A.C. Andrello, W.A. Verri Jr, M.S. Rogers; funding acquisition: M.S. Rogers,, S.A. Missmer, R.M. Anchan; methodology: T.H. Zaninelli, V. Fattori, and M.S. Rogers; human sample collection: S.A. Missmer, A.F. Vitonis, K.L. Terry, R.M. Anchan; animal breading and VEGFR1 ablation: D. Sim and H. Bukhari; resources: A.C. Andrello; D. Bree, T. Zheng, J. Wagner, W.A. Verri Jr, and M.S. Rogers; project administration: T.H. Zaninelli; supervision: V. Fattori, W.A. Verri Jr, and M.S. Rogers; visualization: T.H. Zaninelli, V. Fattori, W.A. Verri Jr, and M.S. Rogers; writing-original draft: T.H. Zaninelli; writing - editing and reviewing: all authors. All authors have read and approved the final version of the manuscript.

pharmacology and toxicology↗

ARID1A maintains transcriptionally repressive H3.3 associated with CHD4-ZMYND8 chromatin interactions

ARID1A is a signature subunit of the mammalian SWI/SNF (BAF) chromatin remodeling complex and is mutated at a high rate in malignancies and benign diseases originating from the uterine endometrium. Through genome-wide analysis of human endometriotic epithelial cells, we show that more than half of ARID1A binding sites are marked by the variant histone H3.3, including active regulatory elements. ARID1A loss leads to H3.3 depletion at ARID1A bound active regulatory elements and a concomitant redistribution of H3.3 towards genic elements. ARID1A interactions with the repressive chromatin remodeler CHD4 (NuRD) are associated with H3.3-containing chromatin regulation. ZMYND8, the CHD4-interacting acetyl-histone H4 reader, specifies ARID1A-CHD4-H3.3 target regulatory activity towards histone H4 lysine 16 acetylation (H4K16ac) to repress super-enhancers. ARID1A, H3.3, CHD4, and ZMYND8 co-repress the expression of genes governing extracellular matrix, motility, adhesion, and epithelial-to-mesenchymal transition. Moreover, these gene expression alterations are observed in human endometriomas. Altogether, these studies demonstrate that cooperation among a histone reader and different types of chromatin remodelers safeguards the endometrium through transcriptionally repressive H3.3.

genetics↗